Legal & General Group
ABCL icon

Legal & General Group’s AbCellera Biologics ABCL Stock Holding History

Legal & General Group’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-27,044
Closed -$204K – 3406
2023
Q1 		$204K Sell
27,044
-280
-1% -$2.54K ﹤0.01% 2580
2022
Q4 		$277K Buy
27,324
+409
+2% +$4.72K ﹤0.01% 2492
2022
Q3 		$266K Buy
26,915
+1,828
+7% +$20.1K ﹤0.01% 2519
2022
Q2 		$267K Buy
+25,087
New +$212K ﹤0.01% 2534

Other funds holding ABCL

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Legal & General Group's ABCL Position: Q2 2023 in Review

Legal & General Group sold out of AbCellera Biologics (ABCL) in Q2 2023, closing a stake of 27,044 shares — an estimated $204K sold.

Legal & General Group first reported a position in ABCL in Q2 2022 and held it in 4 quarters. The position peaked at $277K in Q4 2022. 169 funds tracked by Wall St. Rank hold ABCL as of Q2 2023.

  • Legal & General Group reported no remaining AbCellera Biologics position as of Q2 2023 after selling out during the quarter.
  • Legal & General Group sold 27,044 AbCellera Biologics shares in Q2 2023, an estimated $204K.
  • Legal & General Group first reported a position in AbCellera Biologics in Q2 2022 and held it in 4 quarters.
  • Legal & General Group's AbCellera Biologics position peaked at $277K in Q4 2022.
  • 169 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2023.

Based on Legal & General Group's 13F filing for Q2 2023, filed 14 Aug 2023.